MED25: A Potential Drug Target and Biomarker for RNA polymerase II Transcription Subunit 25

Target Name: MED25

NCBI ID: G81857

MED25

MED25: A Potential Drug Target and Biomarker for RNA polymerase II Transcription Subunit 25

RNA polymerase II (RNA polymerase II or RNA-II) is a key transcription factor that plays a central role in gene expression and cell growth. It is composed of several subunits, including the Mediator of RNA polymerase II transcription subunit 25 (MED25), which is a protein that interacts with the active site of RNA polymerase II and modulates its activity. MED25 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

MED25 is a 21-kDa protein that contains 115 amino acid residues and has a calculated pI of 6.9. It is expressed in a variety of tissues and cells, including muscle, heart, brain, and cancer cells. MED25 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and transcriptional regulation.

One of the most significant functions of MED25 is its role as the Mediator of RNA polymerase II transcription subunit 25. This subunit functions as a critical component of the active site of RNA polymerase II, where the enzyme binds to the DNA template and modulates the transcriptional activity. MED25 has been shown to interact with the active site of RNA polymerase II and regulate the binding of the enzyme to the DNA template.

MED25 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and transcriptional regulation. One of the most significant functions of MED25 is its role as the Mediator of RNA polymerase II transcription subunit 25. This subunit functions as a critical component of the active site of RNA polymerase II, where the enzyme binds to the DNA template and modulates the transcriptional activity. MED25 has been shown to interact with the active site of RNA polymerase II and regulate the binding of the enzyme to the DNA template.

In addition to its role as the Mediator of RNA polymerase II transcription subunit 25, MED25 has also been shown to play a role in cell signaling pathways. For example, MED25 has been shown to be involved in the regulation of theNotch signaling pathway, which is a critical pathway involved in cell growth, survival, and development.

MED25 has also been shown to play a role in the regulation of cellular processes that are important for cancer progression. For example, MED25 has been shown to be involved in the regulation of the T-cell receptor signaling pathway, which is critical for cancer immune surveillance.

In conclusion, MED25 is a protein that has significant roles in various cellular processes, including cell growth, apoptosis, and transcriptional regulation. Its function as the Mediator of RNA polymerase II transcription subunit 25 makes it a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Further research is needed to fully understand the role of MED25 in these processes and to develop effective treatments.

Protein Name: Mediator Complex Subunit 25

Functions: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. Required for RARA/RXRA-mediated transcription

The "MED25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MED25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets